molecules of the month


oral BACE1-selective inhibitor

preclinical, QTc observed in dogs

from literature starting point

Journal of Medicinal Chemistry

Janssen Pharmaceutica NV

1 min read

The Janssen BACE1-selective inhibitor, JNJ-67569762, was a preclinical candidate for Alzheimer’s disease. Obtaining BACE1 over BACE2 selectivity was a major challenge in the field, and the molecule is 74x selective thanks to a bicyclic ring system in the S3 pocket. In in vivo models, BACE1-mediated PD was observed without BACE2-dependent hair depigmentation. The authors chose to work on a 2-amino-tetrahydropyridine scaffold, avoiding the 1,3-thiazine group linked to liver toxicity in clinical trials, and leveraged a sulfonyl group to lower pKa and increase lipophilicity. Unfortunately, in a 14-day dog study, a prolonged QTc signal was observed, despite a large in vitro window against hERG (patch clamp IC50 = 8.3 uM). Potential effects on hERG trafficking were postulated but not investigated further. The…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: